Healthcare Summary: AstraZeneca (NYSE:AZN) Tumbles on Not Meeting Fostamatinib Primary Goals, Sanofi (NYSE:SNY) Give Constructive Results

  on Dec 14,2012 Posted in Business News ,Featured
Share |
We're on   

 AstraZeneca (NYSE:AZN) shares plunged down deeply following the firm stated that it was unable to complete one of two main goals in experimenting fostamatinib, aimed as an oral cure for rheumatoid arthritis.

AstraZeneca plc (ADR) (NYSE:AZN) dropped of -2.94% and closed at $47.46 with the total traded volume 2.10 million shares. AZN has trailing twelve months’ earnings per share of $4.90.

Eli Lilly & Co. (NYSE:LLY) shares plunged fractionally on Thursday as it stated that it would end one of three studies for tabalumab, its personal rheumatoid-arthritis medication, because of an inadequate impact on patients.

Eli Lilly & Co. (NYSE:LLY) shares moved down -1.57% to close at $48.23 and its total traded volume during last trading session was 10.17 million shares.

LLY‘s has market capitalization of $55.97 billion and its beta value stands at 0.67 times.  LLY‘s has current ratio of 2.02 and its debt-to-equity ratio was 0.34.

Sanofi (NYSE:SNY) lately declared optimistic results from a phase II trial assessing the efficiency of its hematology candidate, SAR302503 (selective JAK2 inhibitor) in three dose strengths (300 mg, 400 mg, and 500 mg) for the lowering of spleen volume and enhancement in constitutional symptoms in intermediate-2 or high-risk primary or secondary myelofibrosis (MFGLQ) patients.

Sanofi SA (ADR)(NYSE:SNY) surged+0.51% with the closing price of $46.90. The overall volume in the last trading session was 1.35 million shares. Its fifty two week range was $33.03-$47.15. The total market capitalization remained $123.99 billion.

In its share capital SNY has 2.65billion outstanding shares while 2.32billion shares have been floated in market. SNY has institutional ownership of 8.10%. Company’s current year earnings per share grew with 2.68% while the five years EPS growth rate was +13.44%.

Boston Scientific Corporation (NYSE:BSX)

As of latest close, Boston Scientific Corporation (NYSE:BSX) shares are up about 5.43% for 2012 and recently topped out a 52-week high of $6.41 (2/28/2012). The shares slipped below the 200-Day SMA (-$0.75) and are now standing+3.51% above 50-day SMA. The performance measured for the month was +8.48% and weekly performance appeared at +0.72%.

GlaxoSmithKline plc (ADR) (NYSE:GSK)

The price of the stock moved down-0.61% and finished the day at $43.94 on above average volume. The day started out with a higher opening price of $43.99 versus prior close of $44.21. The total number of shares traded on the latest trading day was about 3.06 million shares, and changed hands at average prices of $43.71 to $44.15apiece. The shares jumped about 1.74% since the start of 2012 and has a -3.05% lose in last three months. Narrowing down the performance period, the stock rose 4.05% for the month and a 1.10% gain over the week.




Leave a Reply